✦ LIBER ✦

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

✍ Scribed by Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Joseph R Walker; Tabassome Simon; Elliott M Antman; Eugene Braunwald; Marc S Sabatine

Book ID: 118553336
Publisher: The Lancet
Year: 2010
Tongue: English
Weight: 294 KB
Volume: 376
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(10)61273-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association of genetic variants in CYP2C

Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: An updated meta-analysis

✍ Yan Ping Liu; Pan Pan Hao; Ming Xiang Zhang; Cheng Zhang; Fei Gao; Yun Zhang; Yu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 358 KB

Effect of CYP2C19 and ABCB1 single nucle

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

✍ Lars Wallentin; Stefan James; Robert F Storey; Martin Armstrong; Bryan J Barratt 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 205 KB

Evaluation of prasugrel compared with cl

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)

✍ Stephen D. Wiviott; Elliott M. Antman; C. Michael Gibson; Gilles Montalescot; Je 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Evaluation of prasugrel compared with cl

✍ Stephen D. Wiviott; Elliott M. Antman; C. Michael Gibson; Gilles Montalescot; Je 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB

The Efficacy and Safety of Prasugrel Wit

The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis

✍ Michelle O'Donoghue; Elliott M. Antman; Eugene Braunwald; Sabina A. Murphy; P. G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 480 KB

Early and Late Benefits of Prasugrel in

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction) Analysis

✍ Elliott M. Antman; Stephen D. Wiviott; Sabina A. Murphy; Juri Voitk; Yonathan Ha 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 287 KB